Health insurance and hospital associations urged HHS to spike the proposed rule to expand access to short-term health insurance, warning it would lead to higher premiums for Affordable Care Act-compliant plans and more uncompensated care delivered at hospitals.
A small number of hospitals and health systems are turning to the courts to challenge Anthem's new policies restricting outpatient imaging and emergency department coverage. Attorneys and industry experts disagree on the cases' merits.
Along with the rest of the industry, Project Japan is eager to hear what President Donald Trump has to say about drug prices. But that's not all we are watching this week.
What could rein in rising drug prices? Project Japan sought to find out.
The FDA is encouraging drugmakers to conduct fewer clinical trials on certain proposed medication-assisted therapies for opioid use disorder, saying a streamlined approach will help patients access treatment quicker.
In the Medical Device Safety Action Plan, FDA regulators set forth ideas for getting safer devices to patients faster.
HHS wants to delay implementing several planned changes to federal policy that governs research on people and human biological specimens.
The Senate will be finishing its portion of the upcoming opioids legislation on April 24. The House and Senate will need to combine their bills in a comprehensive package congressional leaders want passed by the end of May.
The Drug Enforcement Administration has raised production quotas for injectable opioid manufacturers, but relief isn't expected until summer.
Providers are eager to find ways to reduce readmissions, but two new post-acute discharge-related CMS measures don't appear to be the solution.
As the Trump administration and some in Congress whittle away at the Affordable Care Act, blue states are filling in gaps in an attempt to bolster their markets. Others are picking up chainsaws.
A recently unsealed False Claims Act lawsuit filed in 2014 accuses CVS Health, through its pharmacy benefits manager unit, of getting lower prices on drugs with its pharmacies and failing to pass those savings on to Medicare Part D.